# Prostate Cancer

Prostate cancer care requires risk-adapted use of PSA testing, MRI and biopsy, judicious selection of surveillance or definitive local therapy, and stage-specific systemic treatment anchored by androgen deprivation therapy.

**Clinical question:** How should physicians evaluate suspected prostate cancer and select treatment across localized, recurrent, and metastatic disease?

Updated: 2026-08-21T00:42:23.017396+00:00

## What matters in practice
- PSA is a continuous risk marker rather than a diagnostic binary; historical biopsy thresholds have varied from 2.5 to 10 ng/mL across screening trials. [11][12][13]
- Multiparametric prostate MRI can support cancer detection, but tissue diagnosis is required when clinical risk is sufficiently high to justify biopsy. [1][20]
- For localized disease at risk for spread, surgery and/or radiation are standard definitive options; urinary, erectile, and bowel toxicity should materially inform selection. [1]
- Active monitoring, radical prostatectomy, and radiotherapy remain competing strategies for localized disease, with management requiring individualized assessment of tumor risk, life expectancy, and treatment effects. [15]
- ADT is standard care for metastatic prostate cancer and is often combined with radiation in selected patients; treatment choice in advanced disease is increasingly biomarker- and disease-state dependent. [1]
- FDA-approved options now include enzalutamide for high-risk nonmetastatic castration-sensitive biochemical recurrence, darolutamide for metastatic castration-sensitive disease, and lutetium Lu 177 vipivotide tetraxetan for selected PSMA-positive mCRPC. [6][7][8]

## Use PSA as a risk assessment, not a stand-alone biopsy trigger

Interpret PSA in clinical context and plan downstream testing before ordering population screening.

PSA-based screening can detect clinically significant prostate cancer but also produces false-positive results, overdiagnosis, anxiety, and treatment-related harms. The AUA/SUO early-detection guideline emphasizes PSA-based screening with increasing use of biomarkers and multiparametric MRI to identify clinically significant cancer while reducing unnecessary biopsy and detection of low-risk disease. [20]

No single PSA threshold reliably distinguishes cancer from benign disease. Screening trials used biopsy thresholds ranging from 2.5 to 10.0 ng/mL, and historic data indicate that a 3 ng/mL threshold can miss clinically significant cancers. PSA should therefore be treated as a continuous risk estimate integrated with examination findings, prior PSA values, patient risk factors, and patient preferences. [10][11][12][13]

Men considering screening should understand that the purpose is earlier detection of potentially consequential cancer, not diagnosis by PSA alone. The 2018 USPSTF evidence review documents heterogeneous screening intervals, ranging from one-time screening to every 1 to 4 years, and heterogeneous PSA thresholds across trials; these differences contribute to variable screening outcomes and preclude a universal operational threshold. [11]
- Use shared decision-making before PSA screening, explicitly addressing false positives, overdiagnosis, biopsy consequences, and treatment toxicity. [11][20]
- Do not interpret a borderline PSA result in isolation; reassess risk before proceeding to biopsy. [12][13]
- Use MRI and, where appropriate, biomarkers to refine biopsy decisions rather than treating PSA as cancer-confirmatory. [20]

*Initial evaluation decisions supported by available screening and FDA sources. [1][11][20]*

| Clinical finding | Next diagnostic consideration | Rationale |
| --- | --- | --- |
| Elevated or concerning PSA | Reassess overall risk; consider mpMRI and risk-refining tools before biopsy. [20] | PSA thresholds have varied substantially across trials and PSA reflects continuous rather than binary cancer risk. [11][12] |
| High clinical suspicion after risk assessment | Perform prostate biopsy for histologic confirmation and grading. [1] | Biopsy establishes whether cancer is present and characterizes microscopic aggressiveness. [1] |
| Confirmed cancer with concern for extraprostatic spread | Obtain additional staging imaging as needed for treatment planning. [1] | Extent of disease affects appropriateness of local versus systemic treatment. [1] |

## Confirm disease histologically and use grade and extent to direct treatment

The key transition is from PSA-associated risk to pathologically and anatomically defined disease.

MRI may help detect prostate cancer, but it does not replace pathologic diagnosis when cancer suspicion remains sufficient to warrant tissue sampling. Biopsy determines cancer presence and provides histologic assessment of aggressiveness, reported using Gleason score. [1]

After diagnosis, treatment planning depends on the likelihood of disease outside the prostate. FDA notes that additional imaging may be required when the risk of spread is high. This staging step determines whether a local-only approach is adequate or whether systemic therapy, radiation-field expansion, or multidisciplinary evaluation is needed. [1]

Clinical documentation should preserve the disease state at each transition: localized disease, post-local-therapy biochemical recurrence, metastatic castration-sensitive disease, or metastatic castration-resistant disease. These states carry different regulatory indications and systemic treatment options. [4][6][7][8]
- Document biopsy grade because Gleason score is the pathologic descriptor of tumor aggressiveness cited in FDA patient information. [1]
- Assess metastatic risk before choosing definitive local therapy or systemic treatment intensity. [1]
- Reassess disease state at recurrence because castration-sensitive and castration-resistant metastatic disease have distinct approved therapies. [6][7][8]

*Disease-state framework for treatment selection. [1][4][6][7][8]*

| Disease state | Principal decision | Source-supported treatment direction |
| --- | --- | --- |
| Localized cancer | Surveillance versus definitive local treatment | Surgery and/or radiation are preferred treatments when localized disease is at risk for spread. [1] |
| Biochemical recurrence without metastases | Assess risk of metastasis and prior local therapy | Enzalutamide is FDA approved for high-risk nonmetastatic castration-sensitive biochemical recurrence. [6] |
| Metastatic castration-sensitive cancer | Select ADT-based systemic strategy | ADT is standard care for metastatic disease; darolutamide is FDA approved for mCSPC. [1][7] |
| Metastatic castration-resistant cancer | Use prior therapy, molecular status, PSMA expression, and chemotherapy fitness | FDA-supported options include talazoparib with enzalutamide for HRR-mutated disease and PSMA-directed lutetium Lu 177 therapy in eligible patients. [4][8] |

## Match surveillance or definitive therapy to oncologic risk and functional tradeoffs

For clinically localized disease, the central decision is whether treatment benefit justifies immediate morbidity.

Localized prostate cancer management remains controversial because many tumors have an indolent course whereas a subset can progress. In a 15-year trial comparing monitoring, surgery, and radiotherapy for localized prostate cancer, these approaches remained central management strategies, underscoring the need for individualized selection rather than a single default intervention. [15]

FDA identifies radiation therapy and/or surgery as preferred treatment for localized prostate cancer at risk for spread. Radiation may also be administered after surgery in selected patients at high risk of residual prostate cancer. The expected tradeoffs include urinary effects, erectile dysfunction, and bowel problems after surgery or radiation. [1]

Surveillance or monitoring is particularly relevant when the expected natural history is favorable and treatment morbidity is likely to outweigh near-term benefit. A review of prognosis notes that men with well-differentiated disease can often survive 10 to 20 years without intervention, whereas poorly differentiated disease has a less favorable course. This is supportive prognostic context rather than a substitute for contemporary risk stratification. [19]
- Discuss monitoring, prostatectomy, and radiotherapy as distinct options for localized disease; do not frame local treatment as mandatory for every biopsy-detected cancer. [15][19]
- When recommending surgery or radiation, counsel specifically about urinary dysfunction, erectile dysfunction, and bowel toxicity. [1]
- Consider postoperative radiation in patients considered at high risk for residual disease, consistent with FDA patient information. [1]

### Clinical counseling priorities

The decision should make explicit the competing outcomes: cancer control, likelihood of later intervention, urinary function, sexual function, bowel function, and the burden of serial monitoring. Available sources support the existence of these tradeoffs but do not provide sufficient detail to specify modern risk-group thresholds, surveillance schedules, radiation regimens, or surgical selection criteria. [1][15]

*Localized-disease options and decision-relevant tradeoffs. [1][15][19]*

| Approach | When it is considered | Key tradeoff |
| --- | --- | --- |
| Monitoring or active surveillance | Localized disease when immediate treatment morbidity may outweigh benefit and prognosis appears favorable. [15][19] | Requires ongoing reassessment and may defer, rather than eliminate, later treatment. [15] |
| Radical prostatectomy | Localized cancer selected for definitive local therapy. [1][15] | Can affect urinary and erectile function. [1] |
| Radiation therapy | Localized cancer selected for definitive local therapy; may be used postoperatively in selected high-risk patients. [1] | Can affect urinary, erectile, and bowel function. [1] |

## Recognize high-risk biochemical recurrence as a distinct nonmetastatic treatment setting

Recurrence after definitive local therapy may remain nonmetastatic yet carry substantial metastatic risk.

In November 2023, the FDA approved enzalutamide for patients with high-risk nonmetastatic castration-sensitive prostate cancer with biochemical recurrence. Enzalutamide may be administered with or without a gonadotropin-releasing hormone analog. [6]

The FDA-recommended enzalutamide dose in this setting is 160 mg orally once daily with or without food until disease progression or unacceptable toxicity. Treatment may be suspended when PSA becomes undetectable, defined as less than 0.2 ng/mL, after 36 weeks; treatment may be restarted when PSA reaches at least 2.0 ng/mL after radical prostatectomy or at least 5.0 ng/mL after primary radiation therapy. [6]

Reported common adverse reactions differ by use with leuprolide versus monotherapy. With enzalutamide plus leuprolide, common events include hot flush, musculoskeletal pain, fatigue, falls, and hemorrhage; with monotherapy, common events include fatigue, gynecomastia, musculoskeletal pain, breast tenderness, hot flush, and hemorrhage. [6]
- Confirm that the patient fits the FDA-approved high-risk nonmetastatic castration-sensitive biochemical-recurrence population before applying intermittent treatment instructions. [6]
- If using the FDA-described treatment suspension strategy, document prior definitive modality because the PSA restart threshold differs after prostatectomy versus primary radiation. [6]
- Monitor for falls, fatigue, hemorrhage, vasomotor symptoms, and breast symptoms according to regimen. [6]

*FDA-described enzalutamide management for high-risk nonmetastatic castration-sensitive biochemical recurrence. [6]*

| Parameter | FDA-supported approach |
| --- | --- |
| Dose | Enzalutamide 160 mg orally once daily, with or without food. [6] |
| ADT coadministration | May be given with or without a GnRH analog. [6] |
| Potential treatment suspension | May suspend if PSA is undetectable, defined as <0.2 ng/mL, after 36 weeks of therapy. [6] |
| Restart after prostatectomy | Restart when PSA is ≥2.0 ng/mL. [6] |
| Restart after primary radiation | Restart when PSA is ≥5.0 ng/mL. [6] |

## Anchor metastatic castration-sensitive treatment in androgen suppression and intensification

Metastatic castration-sensitive disease warrants systemic treatment rather than local therapy alone.

ADT suppresses testosterone production or blocks androgen action on prostate cancer cells. FDA describes ADT as standard care for metastatic prostate cancer and notes that radiation therapy is sometimes combined with hormone therapy. Loss of testosterone drives many ADT toxicities. [1]

Darolutamide received FDA approval in June 2025 for metastatic castration-sensitive prostate cancer. In the ARANOTE trial, all participants also received a gonadotropin-releasing hormone analog or had prior bilateral orchiectomy, reinforcing that darolutamide is used in the context of maintained castration. [7]

The recommended darolutamide dose is 600 mg orally twice daily with food until disease progression or unacceptable toxicity. The prescribing information includes warnings and precautions for ischemic heart disease, seizure, and embryo-fetal toxicity. [7]
- Maintain medical or surgical castration when using darolutamide for mCSPC. [7]
- Review cardiovascular history and seizure risk before and during darolutamide treatment. [7]
- Counsel that ADT toxicities are largely consequences of testosterone suppression. [1]

*Source-supported systemic treatment elements for metastatic castration-sensitive prostate cancer. [1][7]*

| Therapy | Role | Key operational point |
| --- | --- | --- |
| Androgen deprivation therapy | Standard care for metastatic prostate cancer. [1] | Suppresses testosterone production or blocks androgen action. [1] |
| Darolutamide | FDA approved for mCSPC. [7] | 600 mg orally twice daily with food; use with a GnRH analog or after bilateral orchiectomy. [7] |
| Radiation plus hormone therapy | Used in some patients. [1] | Selection details are not provided in the available source. [1] |

## Use molecular and PSMA testing to identify treatment-eligible mCRPC subsets

mCRPC treatment selection increasingly depends on actionable homologous-recombination repair alterations and PSMA expression.

Talazoparib is FDA labeled in combination with enzalutamide for adults with homologous recombination repair gene-mutated mCRPC. The recommended talazoparib dose is 0.5 mg orally once daily with enzalutamide until disease progression or unacceptable toxicity; patients should also receive a GnRH analog or have undergone bilateral orchiectomy. Moderate or severe renal impairment requires dose reduction and increased monitoring for adverse reactions. [4]

In March 2025, the FDA expanded the indication for lutetium Lu 177 vipivotide tetraxetan to adults with PSMA-positive mCRPC previously treated with an androgen receptor pathway inhibitor and considered appropriate to delay taxane-based chemotherapy. Patients should be selected with gallium Ga 68 gozetotide or another approved PSMA PET agent on the basis of tumor PSMA expression. [8]

The FDA-recommended lutetium Lu 177 vipivotide tetraxetan regimen is 7.4 GBq (200 mCi) intravenously every 6 weeks for up to six doses, or until progression or unacceptable toxicity. Important risks include radiation exposure, myelosuppression, and renal toxicity. [8]

Docetaxel remains an FDA-labeled treatment in metastatic castration-resistant prostate cancer. The supplied label specifies administration only when the neutrophil count is at least 1,500 cells/mm3 and recommends dose reduction from 75 mg/m2 to 60 mg/m2 after febrile neutropenia, prolonged severe neutropenia, severe or cumulative cutaneous reactions, or moderate neurosensory symptoms; persistent toxicity may require reduction to 45 mg/m2. [5]
- Obtain appropriate HRR testing before considering talazoparib plus enzalutamide, because the FDA indication is HRR gene-mutated mCRPC. [4]
- Use approved PSMA PET selection before lutetium Lu 177 vipivotide tetraxetan. [8]
- Monitor blood counts and renal toxicity risk with PSMA radioligand therapy. [8]
- Verify neutrophil count before docetaxel and apply label-specified dose modification for serious hematologic, skin, or neurologic toxicity. [5]

*Selected FDA-supported mCRPC treatments and eligibility requirements. [4][5][8]*

| Treatment | Eligible population or prerequisite | Dose or monitoring detail |
| --- | --- | --- |
| Talazoparib plus enzalutamide | HRR gene-mutated mCRPC; continue GnRH analog or prior bilateral orchiectomy. [4] | Talazoparib 0.5 mg orally once daily with enzalutamide; reduce dose and monitor more closely in moderate or severe renal impairment. [4] |
| Lutetium Lu 177 vipivotide tetraxetan | PSMA-positive mCRPC after ARPI therapy when appropriate to delay taxane chemotherapy; select with an approved PSMA PET product. [8] | 7.4 GBq intravenously every 6 weeks for up to six doses; monitor for myelosuppression and renal toxicity. [8] |
| Docetaxel | Metastatic castration-resistant prostate cancer. [5] | Administer when neutrophils are ≥1,500 cells/mm3; reduce from 75 to 60 mg/m2 for specified serious toxicities. [5] |

## Reassess disease state, treatment toxicity, and patient priorities at every transition

Disease reassessment is necessary because treatment eligibility changes with recurrence, metastatic spread, and castration resistance.

The highest-value recurring task is to define the current disease state accurately and then align testing with an actionable treatment decision. MRI, biopsy, staging imaging, germline or tumor-directed testing where indicated, and PSMA PET each have different purposes; none should be ordered reflexively without a planned consequence for the result. [1][4][8][20]

Treatment-related morbidity must be managed as part of cancer care. Surgery and radiation can affect urinary, sexual, and bowel function; ADT causes effects largely attributable to testosterone loss; darolutamide carries ischemic heart disease and seizure warnings; radioligand therapy can cause myelosuppression and renal toxicity; and docetaxel requires hematologic and toxicity-directed dose modification. [1][5][7][8]

Multidisciplinary discussion is particularly useful when there is uncertainty about local treatment candidacy, postoperative radiation, high-risk biochemical recurrence, molecularly selected mCRPC therapy, or sequencing of radioligand therapy versus taxane chemotherapy. The available sources establish relevant therapies and regulatory criteria but do not provide a complete contemporary sequencing algorithm. [1][4][6][8]
- Record the prior local treatment modality in biochemical recurrence because FDA restart thresholds for enzalutamide differ by prostatectomy versus radiation history. [6]
- Before mCRPC targeted therapy, verify both the actionable biomarker and the regulatory disease-state requirement. [4][8]
- Use current FDA labeling and specialty guidance for complete contraindications, drug interactions, dose modification, and sequencing because several supplied labels are explicitly not current. [2][3][5]

*Monitoring priorities derived from available treatment sources. [1][5][6][7][8]*

| Treatment context | Monitor | Actionable concern |
| --- | --- | --- |
| Enzalutamide for biochemical recurrence | PSA and adverse effects including fatigue, falls, hemorrhage, and breast symptoms depending on regimen. [6] | FDA provides criteria for suspension after undetectable PSA and restart thresholds based on prior local therapy. [6] |
| Darolutamide plus castration | Clinical adverse effects and cardiovascular or neurologic risk. [7] | Warnings include ischemic heart disease and seizure. [7] |
| Lutetium Lu 177 vipivotide tetraxetan | Blood counts and renal toxicity. [8] | Myelosuppression and renal toxicity are recognized risks. [8] |
| Docetaxel | Neutrophil count and treatment-limiting toxicity. [5] | Do not administer if neutrophils are <1,500 cells/mm3; reduce dose for specified toxicities. [5] |

## Common questions

### Is there a single PSA level that mandates prostate biopsy?

No. Historical screening trials used PSA thresholds from 2.5 to 10.0 ng/mL, and PSA should be interpreted as a continuous risk marker with clinical context, MRI, and other risk-refining information rather than as an isolated binary biopsy trigger. [11][12][13][20]

### Does prostate MRI replace biopsy?

No. MRI may help detect prostate cancer and refine biopsy decisions, but biopsy is required to establish cancer diagnosis and assess microscopic aggressiveness when clinical risk warrants tissue sampling. [1][20]

### When is enzalutamide FDA approved for biochemical recurrence?

Enzalutamide is FDA approved for high-risk nonmetastatic castration-sensitive prostate cancer with biochemical recurrence. The FDA dose is 160 mg orally once daily, with or without a GnRH analog. [6]

### What testing is required before lutetium Lu 177 vipivotide tetraxetan?

Patients should have PSMA-positive mCRPC and be selected using gallium Ga 68 gozetotide or another approved PSMA PET product based on tumor PSMA expression. The expanded FDA indication also requires prior ARPI therapy and appropriateness to delay taxane chemotherapy. [8]

### What is required for talazoparib plus enzalutamide in mCRPC?

The FDA indication is HRR gene-mutated mCRPC. Talazoparib is given at 0.5 mg orally once daily with enzalutamide, while maintaining a GnRH analog or prior bilateral orchiectomy; renal impairment requires dose reduction and closer monitoring. [4]

## References
1. Prostate Cancer Symptoms, Tests and Treatments | FDA — www.fda.gov — https://www.fda.gov/consumers/consumer-updates/prostate-cancer-symptoms-tests-and-treatments
2. 3114705 This label may not be the latest approved by FDA ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020180s040s041s042lbl.pdf
3. 3332312 This label may not be the latest approved by FDA ... — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020449s069lbl.pdf
4. Reference ID: 5607383 - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211651s013lbl.pdf
5. docetaxel injection - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/201195s015lbl.pdf
6. FDA approves enzalutamide for non-metastatic castration-sensitive prostate cancer with biochemical recurrence | FDA — www.fda.gov — https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enzalutamide-non-metastatic-castration-sensitive-prostate-cancer-biochemical-recurrence
7. FDA approves darolutamide for metastatic castration-sensitive prostate cancer | FDA — www.fda.gov — https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-darolutamide-metastatic-castration-sensitive-prostate-cancer
8. FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication | FDA — www.fda.gov — https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication
9. PSA Thresholds for Prostate Cancer Detection — jamanetwork.com — https://jamanetwork.com/journals/jama/fullarticle/418071
10. Population-Based Prostate Cancer Screening With ... — jamanetwork.com — https://jamanetwork.com/journals/jamaoncology/fullarticle/2776224
11. USPSTF Recommendation: Screening for Prostate Cancer — jamanetwork.com — https://jamanetwork.com/journals/jama/fullarticle/2680553
12. PSA Thresholds for Prostate Cancer Detection-Reply — jamanetwork.com — https://jamanetwork.com/journals/jama/fullarticle/418072
13. Effect of Verification Bias on Screening for Prostate Cancer ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa021659
14. Prostate cancer - Symptoms, diagnosis and treatment — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/254
15. Fifteen-Year Outcomes after Monitoring, Surgery, or ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa2214122
16. CLINICAL GUIDELINE: PART 1: Early Detection of Prostate ... — annals.org — https://annals.org/cgi/reprint/126/5/394
17. Screening for Prostate Cancer: A Guidance Statement ... — annals.org — https://annals.org/aim/fullarticle/1676183/screening-prostate-cancer-guidance-statement-from-clinical-guidelines-committee-american
18. Urinary Tract Infection | Annals of Internal Medicine — annals.org — https://annals.org/aim/fullarticle/2656219/urinary-tract-infection
19. What Is the Risk Posed by Prostate Cancer? - Oxford Academic — academic.oup.com — https://academic.oup.com/jncimono/article/2012/45/169/951462
20. AUA/SUO Guideline Part I: Prostate Cancer Screening — www.auajournals.org — https://www.auajournals.org/doi/10.1097/JU.0000000000003491
21. Prostate Cancer Clinical Guidelines Panel Summary Report on the Management of Clinically Localized Prostate Cancer | Journal of Urology — www.auajournals.org — https://www.auajournals.org/doi/10.1016/S0022-5347%2801%2966718-1
22. Guideline for the Management of Clinically Localized ... — www.auajournals.org — https://www.auajournals.org/doi/10.1016/j.juro.2007.03.003
23. Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023) — www.auajournals.org — https://www.auajournals.org/doi/10.1097/JU.0000000000003452
24. Local and Locoregional Prostate Cancer — www.esmo.org — https://www.esmo.org/guidelines/living-guidelines/esmo-living-guideline-local-and-locoregional-prostate-cancer

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.